August 20, 2014/Cancer/News & Insight

Guidelines for Peripheral Blood Progenitor Cell Mobilization

Address optimal progenitor cell mobilization strategies for hematopoietic cell transplant

DrDoung_690x380

There are many ways to mobilize peripheral blood progenitor cells, including growth factor or chemotherapy in combination with growth factor, both of which can be enhanced with plerixafor, a fairly new option. Historically, hospitals have applied different protocols and algorithms depending on what resources they had available specifically because mobilization requires coordination between different departments (apheresis, transfusion medicine, flow cytometry) and not every hospital has similar access/availability to these departments.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Because of the imperative need to collect progenitor cells safely, adequately, and cost-effectively and for transplant and to attempt to standardize practices, The American Society of Blood and Marrow Transplantation (ASBMT) set a task force, led by Hien K. Duong, MD, Hematology and Oncology, Cleveland Clinic, to publish evidence-based guidelines for peripheral blood progenitor cell mobilization.

Impact of Plerixafor

With the FDA approval of plerixafor as a mobilizing agent in 2008, a large body of papers and abstracts detailed mobilization and improved efficiency in collection under varied circumstances. Dr. Duong and the ASBMT Practice Guidelines Committee began the process with a thorough literature review of these publications. Dr. Duong and the ASBMT Committee defined evidence-based recommendations to hopefully improve practices throughout the country, whether for small or large hospitals with varying resources.

They address clinical questions such as which growth factor is optimal, what chemotherapy and dose is most effective and when to initiate leukapheresis. The detailed guidelines were peer reviewed by a national expert base representing small and large hospitals and approved by the American Society of Blood and Marrow Transplantation before published in Biology of Blood and Marrow Transplantation.

“We lay out the known risks and benefits, advantages and disadvantages, of each mobilization strategy. We also recommend target cell doses for collection and infusion for transplant. We present data on how cell collection can most safely and effectively be done,” says Dr. Duong. The standardized algorithms address the optimal resource accessibility, and may help smaller transplant programs justify investment in necessary service enhancements. The guidelines even include a list of frequently asked questions, as part of the goal to provide comprehensive guidance.

Photo by Russell Lee.

Advertisement

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

Ad